XML 55 R30.htm IDEA: XBRL DOCUMENT
v3.23.3

Collaborative Arrangements and Licensing Agreements (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
AstraZeneca [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with AstraZeneca (in thousands, except percentages):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with AstraZeneca |  | $ | 15,959 |  |  | $ | 18,107 |  |  | $ | 99,885 |  |  | $ | 55,718 |
Percentage of total revenue |  |  | 11 | % |  |  | 11 | % |  |  | 22 | % |  |  | 13 | %
Biogen [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Biogen (in thousands, except percentages):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Biogen |  | $ | 94,695 |  |  | $ | 88,959 |  |  | $ | 262,599 |  |  | $ | 259,713 |
Percentage of total revenue |  |  | 66 | % |  |  | 56 | % |  |  | 57 | % |  |  | 60 | %
GSK [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with GSK (in thousands, except percentages):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with GSK |  | $ | — |  |  | $ | — |  |  | $ | 15,000 |  |  | $ | — |
Percentage of total revenue |  |  | 0 | % |  |  | 0 | % |  |  | 3 | % |  |  | 0 | %
Novartis [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Novartis (in thousands, except percentages):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Revenue from our relationship with Novartis |  | $ | 1,908 |  |  | $ | — |  |  | $ | 2,023 |  |  | $ | — |
Percentage of total revenue |  |  | 1 | % |  |  | 0 | % |  |  | 0 | % |  |  | 0 | %
Roche [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our relationship with Roche (in thousands, except percentage amounts):
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
R&D revenue |  | $ | 8,858 |  |  | $ | 41,504 |  |  | $ | 16,979 |  |  | $ | 65,360 |
Percentage of total revenue |  |  | 6 | % |  |  | 26 | % |  |  | 4 | % |  |  | 15 | %
Sobi [Member] |
Collaborative Arrangements and Licensing Agreements [Abstract] |
Revenue from Collaborative Relationship | During the three and nine months ended September 30, 2023 and 2022, we earned the following revenue from our distribution agreement with Sobi for TEGSEDI in North America (in thousands, except percentage amounts).
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
TEGSEDI revenue from our distribution agreement with Sobi in North America |  | $ | 794 |  |  | $ | 1,008 |  |  | $ | 2,189 |  |  | $ | 3,443 |
Percentage of total revenue |  |  | 1 | % |  |  | 1 | % |  |  | 2 | % |  |  | 1 | %

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems
Namespace Prefix: | ions_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_AstrazenecaCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_BiogenCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_GlaxoSmithKlineCollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_NovartisCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_RocheCollaborationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_SwedishOrphanBiovitrumABDistributionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |